The prognostic value of immunohistochemical staining for proliferating cell nuclear antigen in synovial sarcoma

Yoshinao Oda, Hiroshi Hashimoto, Setsuko Takeshita, Masazumi Tsuneyoshi

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

Background. The biologic behavior of synovial sarcoma remains a matter of controversy. Some investigators considered proliferative activity to be an important prognostic factor in this tumor. Methods. Fifty‐six patients with synovial sarcoma were immunohistochemically studied with PC10, a monoclonal antibody to proliferating cell nuclear antigen (PCNA). The percentage of nuclear areas with positive staining for PCNA (PCNA score), quantified by using an image analyzer, was compared with nuclear atypia, tumor necrosis, mitoses, and survival. Fifty‐one patients were available for survival analysis. DNA flow cytometry was performed on 30 patients and compared with PCNA score and survival. The prognostic variables were analyzed with a multivariate technique using the Cox hazard model. Results. Nuclear atypia (mild, 14; moderate, 23; severe, 14), mitosis (low, 34; high, 17), and tumor necrosis (< 50%, 37; < 50%, 14) were found to highly affect survival in the log‐rank test (P < 0.01). Sixteen patients with a high (⩾ 12.5) PCNA score had a worse survival (P < 0.01) than did the 35 patients with a low (< 12.5) PCNA score. In patients in whom DNA flow cytometry was performed, the S + G2M‐phase fraction showed no correlation with the clinical outcome. However, there was a significant relationship between the extent of PCNA staining and S + G2M fraction (correlation coefficient [CC] = 0.54; P = 0.002), although the CC between PCNA staining and the mitotic count was only 0.38. However, the ploidy pattern was not related to PCNA scores or prognosis. In a multivariate analysis, a high PCNA score (P = 0.017) and severe nuclear atypia (P = 0.0003) were strong prognostic factors. Conclusions. The results suggest that a high PCNA score is one of the poor prognostic factors in synovial sarcoma.

Original languageEnglish
Pages (from-to)478-485
Number of pages8
JournalCancer
Volume72
Issue number2
DOIs
Publication statusPublished - Jan 1 1993
Externally publishedYes

Fingerprint

Synovial Sarcoma
Proliferating Cell Nuclear Antigen
Staining and Labeling
Survival
Proportional Hazards Models
Mitosis
Flow Cytometry
Necrosis
Neoplasms
Ploidies
DNA
Survival Analysis
Multivariate Analysis
Monoclonal Antibodies
Research Personnel

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

The prognostic value of immunohistochemical staining for proliferating cell nuclear antigen in synovial sarcoma. / Oda, Yoshinao; Hashimoto, Hiroshi; Takeshita, Setsuko; Tsuneyoshi, Masazumi.

In: Cancer, Vol. 72, No. 2, 01.01.1993, p. 478-485.

Research output: Contribution to journalArticle

Oda, Yoshinao ; Hashimoto, Hiroshi ; Takeshita, Setsuko ; Tsuneyoshi, Masazumi. / The prognostic value of immunohistochemical staining for proliferating cell nuclear antigen in synovial sarcoma. In: Cancer. 1993 ; Vol. 72, No. 2. pp. 478-485.
@article{043b273545684b28a069fdac39d0484e,
title = "The prognostic value of immunohistochemical staining for proliferating cell nuclear antigen in synovial sarcoma",
abstract = "Background. The biologic behavior of synovial sarcoma remains a matter of controversy. Some investigators considered proliferative activity to be an important prognostic factor in this tumor. Methods. Fifty‐six patients with synovial sarcoma were immunohistochemically studied with PC10, a monoclonal antibody to proliferating cell nuclear antigen (PCNA). The percentage of nuclear areas with positive staining for PCNA (PCNA score), quantified by using an image analyzer, was compared with nuclear atypia, tumor necrosis, mitoses, and survival. Fifty‐one patients were available for survival analysis. DNA flow cytometry was performed on 30 patients and compared with PCNA score and survival. The prognostic variables were analyzed with a multivariate technique using the Cox hazard model. Results. Nuclear atypia (mild, 14; moderate, 23; severe, 14), mitosis (low, 34; high, 17), and tumor necrosis (< 50{\%}, 37; < 50{\%}, 14) were found to highly affect survival in the log‐rank test (P < 0.01). Sixteen patients with a high (⩾ 12.5) PCNA score had a worse survival (P < 0.01) than did the 35 patients with a low (< 12.5) PCNA score. In patients in whom DNA flow cytometry was performed, the S + G2M‐phase fraction showed no correlation with the clinical outcome. However, there was a significant relationship between the extent of PCNA staining and S + G2M fraction (correlation coefficient [CC] = 0.54; P = 0.002), although the CC between PCNA staining and the mitotic count was only 0.38. However, the ploidy pattern was not related to PCNA scores or prognosis. In a multivariate analysis, a high PCNA score (P = 0.017) and severe nuclear atypia (P = 0.0003) were strong prognostic factors. Conclusions. The results suggest that a high PCNA score is one of the poor prognostic factors in synovial sarcoma.",
author = "Yoshinao Oda and Hiroshi Hashimoto and Setsuko Takeshita and Masazumi Tsuneyoshi",
year = "1993",
month = "1",
day = "1",
doi = "10.1002/1097-0142(19930715)72:2<478::AID-CNCR2820720225>3.0.CO;2-P",
language = "English",
volume = "72",
pages = "478--485",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "2",

}

TY - JOUR

T1 - The prognostic value of immunohistochemical staining for proliferating cell nuclear antigen in synovial sarcoma

AU - Oda, Yoshinao

AU - Hashimoto, Hiroshi

AU - Takeshita, Setsuko

AU - Tsuneyoshi, Masazumi

PY - 1993/1/1

Y1 - 1993/1/1

N2 - Background. The biologic behavior of synovial sarcoma remains a matter of controversy. Some investigators considered proliferative activity to be an important prognostic factor in this tumor. Methods. Fifty‐six patients with synovial sarcoma were immunohistochemically studied with PC10, a monoclonal antibody to proliferating cell nuclear antigen (PCNA). The percentage of nuclear areas with positive staining for PCNA (PCNA score), quantified by using an image analyzer, was compared with nuclear atypia, tumor necrosis, mitoses, and survival. Fifty‐one patients were available for survival analysis. DNA flow cytometry was performed on 30 patients and compared with PCNA score and survival. The prognostic variables were analyzed with a multivariate technique using the Cox hazard model. Results. Nuclear atypia (mild, 14; moderate, 23; severe, 14), mitosis (low, 34; high, 17), and tumor necrosis (< 50%, 37; < 50%, 14) were found to highly affect survival in the log‐rank test (P < 0.01). Sixteen patients with a high (⩾ 12.5) PCNA score had a worse survival (P < 0.01) than did the 35 patients with a low (< 12.5) PCNA score. In patients in whom DNA flow cytometry was performed, the S + G2M‐phase fraction showed no correlation with the clinical outcome. However, there was a significant relationship between the extent of PCNA staining and S + G2M fraction (correlation coefficient [CC] = 0.54; P = 0.002), although the CC between PCNA staining and the mitotic count was only 0.38. However, the ploidy pattern was not related to PCNA scores or prognosis. In a multivariate analysis, a high PCNA score (P = 0.017) and severe nuclear atypia (P = 0.0003) were strong prognostic factors. Conclusions. The results suggest that a high PCNA score is one of the poor prognostic factors in synovial sarcoma.

AB - Background. The biologic behavior of synovial sarcoma remains a matter of controversy. Some investigators considered proliferative activity to be an important prognostic factor in this tumor. Methods. Fifty‐six patients with synovial sarcoma were immunohistochemically studied with PC10, a monoclonal antibody to proliferating cell nuclear antigen (PCNA). The percentage of nuclear areas with positive staining for PCNA (PCNA score), quantified by using an image analyzer, was compared with nuclear atypia, tumor necrosis, mitoses, and survival. Fifty‐one patients were available for survival analysis. DNA flow cytometry was performed on 30 patients and compared with PCNA score and survival. The prognostic variables were analyzed with a multivariate technique using the Cox hazard model. Results. Nuclear atypia (mild, 14; moderate, 23; severe, 14), mitosis (low, 34; high, 17), and tumor necrosis (< 50%, 37; < 50%, 14) were found to highly affect survival in the log‐rank test (P < 0.01). Sixteen patients with a high (⩾ 12.5) PCNA score had a worse survival (P < 0.01) than did the 35 patients with a low (< 12.5) PCNA score. In patients in whom DNA flow cytometry was performed, the S + G2M‐phase fraction showed no correlation with the clinical outcome. However, there was a significant relationship between the extent of PCNA staining and S + G2M fraction (correlation coefficient [CC] = 0.54; P = 0.002), although the CC between PCNA staining and the mitotic count was only 0.38. However, the ploidy pattern was not related to PCNA scores or prognosis. In a multivariate analysis, a high PCNA score (P = 0.017) and severe nuclear atypia (P = 0.0003) were strong prognostic factors. Conclusions. The results suggest that a high PCNA score is one of the poor prognostic factors in synovial sarcoma.

UR - http://www.scopus.com/inward/record.url?scp=0027311890&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027311890&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(19930715)72:2<478::AID-CNCR2820720225>3.0.CO;2-P

DO - 10.1002/1097-0142(19930715)72:2<478::AID-CNCR2820720225>3.0.CO;2-P

M3 - Article

VL - 72

SP - 478

EP - 485

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 2

ER -